News

Allos Therapeutics reports financial

Tuesday, January 11, 2011

Allos Therapeutics (Westminster) reported financial results for 2010 and key priorities for 2011.  Included among the results were sales of $11.8M for FOLOTYN for the fourth quarter of the year, a 27% sequential increase over the previous quarter. 

Luca Technologies appointment

Tuesday, January 11, 2011

Luca Technologies Inc. (Golden), the leading developer of energy farming technologies and producer of sustainable natural gas, today announced the appointment of Matt Micheli Senior Corporate Counsel and Head of Government and Regulatory Affairs. Effective today, Mr. Micheli will be responsible for the advancement of Luca Technologies' regulatory affairs and permitting processes. 

Greg Pfahl Promoted to Audit Partner

Monday, January 10, 2011

DENVER, COLORADO (January 10, 2011) – Hein & Associates, a leading accounting and advisory firm with offices in Denver, Houston, Dallas and Southern California, has promoted Greg Pfahl to Audit Partner in the Denver office. In addition, Michelle Carr and Nicole Toerber were promoted to Audit Senior Manager, and Jessica Carsella to Audit Manager. Jacque Nason was promoted to Business Advisory Services Supervisor. 

Able Planet wins three awards

Monday, January 10, 2011

Able Planet Incorporated (Denver) announced that it won three Innovations Design and Engineering Awards from the 2011 International Consumer Electronics Show. Products are judged by a preeminent panel of independent industrial designers, engineers and members of the trade press to honor outstanding design and engineering in cutting edge consumer electronics. Able Planet was founded on a hearing technology that enabled people with profound hearing loss to distinguish hard to hear sounds and has expanded to also provide innovation in consumer electronics. 

Covidien announces the availability of the technology

Monday, January 10, 2011

Covidien (Boulder) announced the availability of the new Infinity® MCable® with Nellcor™ OxiMax™ technology as an integrated component of the Dräger Infinity Acute Care System™ in Europe. This system includes the portable Infinity M540 monitor. The Infinity MCable with Nellcor OxiMax technology adds two vital features to the compact Dräger monitor: Nellcor OxiMax specialty pulse oximetry sensors and Nellcor SatSeconds™ alarm management technology.  

InDevR announces promising results

Monday, January 10, 2011

InDevR (Boulder) announced promising results from a blind study to test the effectiveness of the company’s ViroCyt™ Virus Counter® for virus quantification.  The results, published in the January issue of Journal of Virological Methods, “indicate that the Virus Counter provides a reliable means to quantify baculovirus samples... in a fraction of time required to conduct a plaque assay.” This method could streamline research and development efforts for vaccine manufacturers, pharmaceutical and biotechnology companies and researchers worldwide. 

Omni Bio announces that U.S. Patent

Monday, January 10, 2011

Omni Bio Pharmaceutical, Inc. (Greenwood Village) announced that U.S. Patent No. 7,850,970, entitled "Inhibitors of Serine Protease Activity and Their Use in Methods and Compositions for Treatment of Bacterial Infections," was issued by the United States Patent and Trademark Office (USPTO) on December 14, 2010 (the "New Patent"). The New Patent is part of the technology licensed to Omni Bio through one of its technology license agreements with the University of Colorado Denver. The New Patent covers inhibition of all forms of Bacillus anthracis infection (commonly known as anthrax) using one or more of four new peptides made up of 10 linked amino acids.  

ARCA biopharma President panelist

Wednesday, January 05, 2011

ARCA biopharma, Inc. (Broomfield) announced that Dr. Michael Bristow, President and Chief Executive Officer was a featured panelist at the Personalized Medicine Coalition’s Conference, New Frontiers in Personalized Medicine: Cardiovascular Research and Clinical Care, January 6, 2011 at the George Washington University.  Dr. Bristow spoke on “Development of New Treatments and Treatment Strategies for Heart Failure.”  

Array CEO at J.P. Morgan Healthcare Conference

Tuesday, January 04, 2011

Array BioPharma Inc. (Boulder) announced that its Chief Executive Officer, Robert E. Conway, will speak at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 12. 

Pico-Tesla announces expanded Phase III clinical trial

Tuesday, January 04, 2011

Pico-Tesla (Littleton) announced that it has expanded its ongoing Phase III pivotal clinical trial by adding three Principal Investigators, including two university-affiliated clinicians: one in Denver; and one in Tampa. In addition, Pico-Tesla announced that enrollment is approaching 50% of the patients required for this pivotal clinical trial.  The purpose of the ongoing Phase III pivotal clinical trial is to demonstrate the efficacy of Magneceutical® Therapy as an adjunctive therapy to improving aspects of health and quality of life that are relevant to patients with Parkinson's disease.